Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

References

• Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand 1944;117(3-4):216-47
   Google Scholar
• Gertz MA. Waldenstrom macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015;90(4):346-54
   PubMed Web of Science ®Google Scholar
• Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012;118(15):3793-800
   PubMed Web of Science ®Google Scholar
• Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi155-9
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, epidemiology and end results database. Br J Haematol 2015;169(1):81-9
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 2013;88(1):60-5
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Hunter ZR, et al. Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: An analysis of the SEER database. Cancer 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kapoor P, Paludo J, Vallumsetla N, et al. Waldenstrom macroglobulinemia: What a hematologist needs to know. Blood Rev 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012;119(19):4462-6
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30(2):110-15
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012;367(9):826-33
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia 2014;28(8):1698-704
   PubMed Web of Science ®Google Scholar
• Wang Z, Fritschle W, Bennington R, et al. MYD88 L265P mutation detection: analysis of flow cytometry sorted plasma and lymphoid cell clones improves sensitivity and specificity for wm/lpl diagnosis (Abstract 1645). Blood (ASH Annual Meeting Abstracts) 2014;124(21):1645
   PubMedGoogle Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113(18):4163-70
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth international Workshop. Br J Haematol 2013;160(2):171-6
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in waldenstrom macroglobulinemia. Blood 2013;122(7):1222-32
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123(11):1637-46
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123(18):2791-6
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol 2015;168(5):701-7
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia 2015;29(1):169-76
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenstrom’s macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 2009;9(1):36-8
   PubMedGoogle Scholar
• Gutierrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom’s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007;21(3):541-9
   PubMed Web of Science ®Google Scholar
• Leblebjian H, Agarwal A, Ghobrial I. Novel treatment options for Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(Suppl 2):S310-16
   PubMed Web of Science ®Google Scholar
• Gaudette BT, Boise LH. Mir-155 Expression raises the apoptotic threshold in Waldenström macroglobulinemia by inhibition of FOXO3a and Bim (Abstract 1671). Blood (ASH Annual Meeting Abstracts) 2014;124(21):1671
   Google Scholar
• FDA. FDA expands approved use of imbruvica for rare form of non-Hodgkin lymphoma. 2015. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432123.htm [Last accessed 4 may 2015]
   Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015;372(15):1430-40
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008;111(9):4752-63
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13(11):3320-5
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(12):1570-5
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27(23):3830-5
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol 2010;85(9):670-4
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1422-8
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 2013;122(19):3276-82
   PubMed Web of Science ®Google Scholar
• Rosenthal AC, et al. A Phase II clinical trial of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBor-D) in relapsed low grade and mantle cell lymphoma (Abstract 4410). Blood (ASH Annual Meeting Abstracts) 2014;124(21):4410
   Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood 2014;124(4):503-10
   PubMed Web of Science ®Google Scholar
• Siegel DS, et al. Updated results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenström macroglobulinemia (WM) (Abstract 1715). Blood (ASH Annual Meeting Abstracts) 2014;124(21):1715
   PubMedGoogle Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2009;15(1):355-60
   PubMed Web of Science ®Google Scholar
• Leleu X, et al. Lenalidomide is safe and active in Waldenstrom macroglobulinemia (WM) (Abstract 4478). Blood (ASH Annual Meeting Abstracts) 2014;124(21):4478
   Google Scholar
• Rosenthal AC, Amylou CD, Katherine G, et al. A Phase 2 Study of lenalidomide, rituximab, cyclophosphamide and dexamethasone (LR-CD) for untreated low grade non-Hodgkin lymphoma requiring therapy: Waldenström’s macroglobulinemia cohort Results (Abstract 4352). Blood (ASH Annual Meeting Abstracts) 2013;122:21
   Google Scholar
• Thomas SK, Georgina MA, Feng L, et al. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) waldenström’s macroglobulinemia (WM) (Abstract 8536). J Clin Oncol 2014;32(suppl):5S
   Google Scholar
• Leleu X, Jia X, Runnels J, et al. The akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110(13):4417-26
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Husu EN, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010;115(3):559-69
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am J Hematol 2014;89(3):237-42
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, et al. Final results of Phase I/II trial of the oral mTOR inhibitor everolimus (RAD001) in combination with bortezomib and rituximab (RVR) in relapsed or refractory Waldenstrom macroglobulinemia (Abstract 3081). Blood (ASH Annual Meeting Abstracts) 2014;124(21):3081
   PubMedGoogle Scholar
• Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18
   PubMed Web of Science ®Google Scholar
• Flinn I, et al. A Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL (Abstract 802). Blood (ASH Annual Meeting Abstracts) 2014;124(21):802
   Web of Science ®Google Scholar
• Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109(11):4964-72
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Moreau P, Harris B, et al. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res 2012;18(18):5043-50
   PubMed Web of Science ®Google Scholar
• Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 2013;22(9):1211-23
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013;121(8):1296-303
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):133-5
   PubMed Web of Science ®Google Scholar
• Rummel M.J, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cheson BD, Crawford J. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. Br J Haematol 2015;169(4):528-33
   PubMed Web of Science ®Google Scholar
• Furman RR, et al. A Phase II Trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemia (Abstract 3701). Blood (ASH Annual Meeting Abstracts) 2011;118(21):3701
   Google Scholar
• Kanan S, et al. Clinical Characteristics of rituximab intolerance in patients with Waldenstrom’s macroglobulinemia. Blood 2014;124:2610-0
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011;118(2):276-81
   PubMed Web of Science ®Google Scholar
• Liu X, et al. Direct targeting of MYD88 homodimerization in Waldenstrom’s Macroglobulinemia, in IWWM-8. IWWM; London: 2014
   Google Scholar
• Buhrlage S. Kinome targets and inhibitors in WM, in IWWM-8. IWWM; London: 2014
   Google Scholar
• Lim KH, Barton GM, Staudt LM, Oncogenic MYD88 mutants require Toll-like receptors, in AACR. AACR; Washington DC: 2013
   Google Scholar
• Wang D, Jiang W, Sullivan T, et al. Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab (Abstract 508). Blood (ASH Annual Meeting Abstracts) 2014;124(21):508
   Google Scholar
• Balasubramanian WR, et al. Novel IRAK-4 inhibitors exhibit highly potent anti-proliferative activity in DLBCL cell lines with activating MYD88 L265P mutation. AACR; Philadephia: 2015
   Google Scholar
• Vajda E.G, et al. IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B cell lymphomas. AACR; Philadelphia: 2015
   Google Scholar
• Fegan C, et al. The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL) (Abstract 3328). Blood (ASH Annual Meeting Abstracts) 2014. 124(21):3328
   Google Scholar
• Ngo HT, Leleu X, Lee J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008;112(1):150-8
   PubMed Web of Science ®Google Scholar
• McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014;123(15):2308-16
   PubMed Web of Science ®Google Scholar
• Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 and CXCR4 mutated Waldenstrom macroglobulinaemia cells. Br J Haematol 2015;170(1):134-8
   PubMed Web of Science ®Google Scholar
• Paulus A, Akhtar S, Yoon H, et al. Targeted. disruption of USP14 and UCHL5 with the novel deubiquitinase enzyme (DUB) inhibitor, VLX1570, induces immense proteotoxicity and cell death in malignant plasma cells (abstract 3116). Blood (ASH Annual Meeting Abstracts) 2014;124(21):3116
   Google Scholar
• Smith EL, Palomba ML, Park JH, Brentjens RJ. A systemic xenograft model of Waldenström’s macroglobulinemia demonstrates the potent anti-tumor effect of second generation CD19 directed chimeric antigen receptor modified T cells in this disease (Abstract 4484). Blood (ASH Annual Meeting Abstracts) 2014;124(21):4484
   Web of Science ®Google Scholar
• Maddocks KJ, Cohen JB, Christian B, et al. A phase II study of MLN8237 (Alisertib) alone and in combination with rituximab in patients with relapsed or refractory B-cell non-hodgkin lymphomas (NHL) (Abstract 3082). Blood (ASH Annual Meeting Abstracts) 2014;124(21):3082
   Google Scholar
• Azab K, Paulus A, Azab F, et al. A novel and personalized method using simulation for predicting effective therapeutics for Waldenströms macroglobulinemia (Abstract 3024). Blood (ASH Annual Meeting Abstracts) 2014;124(21):3024
   Google Scholar
• Phase 0/1 Biomarker and pharmacodynamic study of roflumilast in patients with advanced B-cell hematologic malignancies (CTRC# 13-0013). Available from: https://clinicaltrials.gov/ct2/show/NCT01888952
   Google Scholar
• An Open-label, Phase 1b study of ACP 196 in subjects with Waldenström macroglobulinemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02180724
   Google Scholar
• Phase 1/2 dose escalation study in patients with relapsed or refractory Waldenstrom’s macroglobulinemia (8400-401). Available from: https://clinicaltrials.gov/ct2/show/NCT02092909
   Google Scholar
• Immunotherapy for asymptomatic phase lymphoplasmacytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01209871
   Google Scholar
• Study of the glutaminase inhibitor CB-839 in hematological tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT02071888
   Google Scholar
• Open-label study of the safety and activity of oprozomib in patients with hematologic malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01416428
   Google Scholar
• A Phase I trial of DI-B4 in patients with advanced CD19 positive indolent B-cell malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01805375
   Google Scholar
• ACP-196 in Combination with pembrolizumab, for treatment of B-cell malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT02362035
   Google Scholar
• Laboratory treated t cells in treating patients with relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01865617
   Google Scholar
• Vincristine sulfate liposome injection (Marqibo®), bendamustine and rituximab—Phase I trial in indolent B-cell lymphoma (BRiM). Available from: https://clinicaltrials.gov/ct2/show/NCT02257242
   Google Scholar
• Alisertib in combination with vorinostat in treating patients with relapsed or recurrent Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or peripheral T-cell lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01567709
   Google Scholar
• Ibrutinib in treating relapsed or refractory B-cell non-Hodgkin lymphoma in patients with HIV infection. Available from: https://clinicaltrials.gov/ct2/show/NCT02109224
   Google Scholar
• Alisertib and romidepsin in treating patients with relapsed or refractory B-cell or T-cell lymphomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01897012
   Google Scholar
• Lenalidomide and ibrutinib in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01955499
   Google Scholar
• Romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Available from: https://clinicaltrials.gov/ct2/show/NCT01638533
   Google Scholar
• Cellular immunotherapy following cyclophosphamide in treating patients with recurrent non-Hodgkin lymphomas, chronic lymphocytic leukemia or B-cell prolymphocytic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02153580
   Google Scholar
• Study of BKM120 & rituximab in patients with relapsed or refractory indolent B-cell lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02049541
   Google Scholar
• Rituximab, Romidepsin, and Lenalidomide in treating patients with recurrent or refractory B-cell non-Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02281279
   Google Scholar
• Panobinostat and everolimus in treating patients with recurrent multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00918333
   Google Scholar
• CPI-613, bendamustine hydrochloride, and rituximab in treating patients with relapsed or refractory B-Cell Non-Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02168907
   Google Scholar
• Cellular immunotherapy following cyclophosphamide in treating patients with recurrent non-Hodgkin lymphomas, chronic lymphocytic leukemia or B-cell prolymphocytic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02153580
   Google Scholar
• Brentuximab vedotin + rituximab as frontline therapy for Pts w/CD30+ and/or EBV+ Lymphomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01805037
   Google Scholar
• Lenalidomide and combination chemotherapy (DA-EPOCH-R) in treating patients with MYC-associated B-Cell lymphomas. Available from: https://clinicaltrials.gov/ct2/show/NCT02213913
   Google Scholar
• Safety, tolerability, and pharmacokinetics of idelalisib in Japanese adults with relapsed or refractory indolent b-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02242045
   Google Scholar
• Safety study of the selective inhibitor of nuclear export (SINE) KPT-330 in patients with advanced hematological cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01607892
   Google Scholar
• ACP-196 in combination with ACP-319, for treatment of B-cell malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT02328014
   Google Scholar
• Romidepsin + oral 5-azacitidine in relapsed/refractory lymphoid malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01998035
   Google Scholar
• Pralatrexate + romidepsin in relapsed/refractory lymphoid malignancies (PDX+Romi). Available from: https://clinicaltrials.gov/ct2/show/NCT01947140
   Google Scholar
• Dendritic cell vaccine in treating patients with indolent b-cell lymphoma or multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT00937183
   Google Scholar
• Carfilzomib plus belinostat in relapsed/refractory NHL. Available from: https://clinicaltrials.gov/ct2/show/NCT02142530
   Google Scholar
• Everolimus and bortezomib in treating patients with relapsed or refractory lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00671112
   Google Scholar
• randomised trial in Waldenstrom’s macroglobulinaemia (R2W). Available from: https://clinicaltrials.gov/ct2/show/NCT01592981
   Google Scholar
• Study of phosphatidylinositol-3-kinase (pi3k) inhibitor idelalisib (gs-1101) in Waldenström macroglobulinemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02439138
   Google Scholar
• A study of belimumab in treating symptomatic Waldenstroms macroglobulinaemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01142011
   Google Scholar
• Trial of ixazomib, dexamethasone and rituximab in patients with untreated Waldenstrom’s macroglobulinemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02400437
   Google Scholar
• Fase II study with brb for non-Hodgkin lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia’s (FIL_BRB). Available from: https://clinicaltrials.gov/ct2/show/NCT02371148
   Google Scholar
• A Phase II study of carfilzomib in relapsed Waldenström’s macroglobulinemia (WM) IST-CAR-531. Available from: https://clinicaltrials.gov/ct2/show/NCT01813227
   Google Scholar
• A Phase II study of doxycycline in relapsed NHL. Available from: https://clinicaltrials.gov/ct2/show/NCT02086591
   Google Scholar
• Panobinostat in treating patients with relapsed or refractory non-Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01261247
   Google Scholar
• Alisertib with and without rituximab in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01812005
   Google Scholar
• A Phase 2 of Entospletinib in subjects with relapsed or refractory hematologic malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01799889
   Google Scholar
• Ibrutinib with rituximab in adults with Waldenström’s macroglobulinemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02165397
   Google Scholar
• Trial comparing chlorambucil to fludarabine in patients with advanced Waldenström macroglobulinemia. Available from: https://clinicaltrials.gov/ct2/show/nct00566332
   Google Scholar
• Efficacy and safety of idelalisib (gs-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (Yosemite). Available from: https://clinicaltrials.gov/ct2/show/
   Google Scholar